Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
11.67
+0.55 (4.95%)
May 14, 2026, 4:00 PM EDT - Market closed
Zevra Therapeutics Employees
Zevra Therapeutics had 61 employees as of December 31, 2025. The number of employees increased by 2 or 3.39% compared to the previous year.
Employees
61
Change (1Y)
2
Growth (1Y)
3.39%
Revenue / Employee
$2,004,738
Profits / Employee
$1,918,049
Market Cap
691.65M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 61 | 2 | 3.39% | 61 | 0 |
| Dec 31, 2024 | 59 | -10 | -14.49% | 59 | 0 |
| Dec 31, 2023 | 69 | 33 | 91.67% | 65 | 4 |
| Dec 31, 2022 | 36 | 12 | 50.00% | 32 | 4 |
| Dec 31, 2021 | 24 | 2 | 9.09% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Allogene Therapeutics | 152 |
| Sutro Biopharma | 137 |
| Kyverna Therapeutics | 130 |
| Solid Biosciences | 121 |
| BridgeBio Oncology Therapeutics | 92 |
| Aclaris Therapeutics | 73 |
| Candel Therapeutics | 55 |
ZVRA News
- 2 days ago - Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewsWire
- 6 days ago - Zevra Therapeutics price target raised to $25 from $23 at Guggenheim - TheFly
- 7 days ago - Zevra Therapeutics reports Q1 EPS 60c, consensus 8c - TheFly
- 7 days ago - Zevra Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 8 days ago - Zevra Reports First Quarter 2026 Financial Results and Corporate Update - GlobeNewsWire
- 7 weeks ago - Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Zevra Therapeutics sells SDX portfolio to Commave for $50M - TheFly
- 2 months ago - Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million - GlobeNewsWire